For the quarter ending 2025-09-30, MAZE had $52,232K increase in cash & cash equivalents over the period. -$24,710K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -30,087 | -66,465 |
| Depreciation | 571 | 1,333 |
| Stock-based compensation expense | 3,864 | 6,463 |
| Non-cash lease expense | 787 | 1,543 |
| Accretion of discounts on marketable securities | 278 | - |
| Other items, net | 0 | 21 |
| Prepaid expenses and other current assets | 758 | 1,750 |
| Other assets | -356 | -18 |
| Accounts payable | -748 | 1,846 |
| Accrued expenses and other liabilities | 2,476 | -957 |
| Operating lease liabilities | -825 | -1,620 |
| Net cash (used in) provided by operating activities | -24,642 | -59,568 |
| Purchases of marketable securities | 66,815 | - |
| Purchases of property and equipment | 68 | 692 |
| Net cash used in investing activities | -66,883 | -692 |
| Proceeds from initial public offering, net of offering costs paid | 0 | 127,752 |
| Proceeds from private placement, net of offering costs paid | 141,748 | - |
| Proceeds from exercise of stock option awards, net of repurchases | 2,009 | 126 |
| Proceeds from issuance of common stock under the 2025 employee stock purchase plan | 0 | 612 |
| Payment of success fee derivative | 0 | 500 |
| Net cash provided by financing activities | 143,757 | 127,990 |
| Net increase in cash, cash equivalents, and restricted cash | 52,232 | 67,730 |
| Cash and cash equivalents at beginning of period | 197,900 | - |
| Cash and cash equivalents at end of period | 317,862 | - |
Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)